Matthew Vincent Dolan - 15 Mar 2022 Form 4 Insider Report for DEXCOM INC (DXCM)

Role
SVP Corporate Development
Signature
By: Jereme Sylvain For: Matthew V Dolan
Issuer symbol
DXCM
Transactions as of
15 Mar 2022
Net transactions value
-$928,359
Form type
4
Filing time
17 Mar 2022, 16:30:27 UTC
Previous filing
10 Mar 2022
Next filing
06 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DXCM Common Stock Sale $419,009 -1,016 -12% $412.41 7,804 15 Mar 2022 Direct F1, F2
transaction DXCM Common Stock Sale $291,550 -686 -8.8% $425.00 7,118 16 Mar 2022 Direct F1, F2
transaction DXCM Common Stock Sale $217,800 -484 -6.8% $450.00 6,634 17 Mar 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2 Included in this number are 6,634 unvested restricted stock units, 2,889 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,048 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,697 of which were granted on March 8, 2020 and shall vest through March 8, 2023.